Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Completed 11Recruiting 4Terminated 3Active not recruiting 3Withdrawn 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 50Sarcoma 9CNS 8Thoracic 4Tumor-Agnostic 3Gynecologic 3Other solid neoplasm 2Genitourinary 2Breast 2Other hematologic neoplasm 1Lymphoid 1Endocrine 1Dermatologic 1

Conditions

Ovarian Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 45Paclitaxel 45Carboplatin 39Magnetic Resonance Spectroscopy 28olaparib 27Specimen Handling 26Cisplatin 24Bevacizumab 20Nivolumab 18Taxes 17Biopsy 16Gemcitabine 13Cyclophosphamide 13durvalumab 12Immunoglobulin G 11Doxorubicin 11Disulfides 11Surveys and Questionnaires 10niraparib 9liposomal doxorubicin 9dostarlimab 9Radiotherapy 8Brachytherapy 8lenvatinib 7fludarabine 7atezolizumab 7Letrozole 7Docetaxel 7cediranib 6Platinum 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Irinotecan × Gynecologic × Clear all
NCT06459180 2026-05-27

TroFuse-020

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
686 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡